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Abstract: Despite providing a consistent and comprehensible format for over-the-counter (OTC)
drug communication, research suggests important limitations in the communication effectiveness of
the Drug Facts Label required on OTC drugs in the United States. This literature is reviewed and
some of these critical limitations of the Drug Facts Label (DFL) highlighted. These include difficulty
communicating complex information that requires integration of multiple pieces of label information
and limited adaptability to serve the unique needs of individual populations (e.g., low literacy or
older consumers). Potential ways to improve the DFL’s communication effectiveness are identified
along with complementary opportunities to improve OTC drug communication by leveraging the
role of pharmacists and use of adjunctive technologies.
Keywords: Drug Facts Label; over-the-counter drugs; label comprehension; self-selection; actual use;
pharmacists; technology; consumer
1. Introduction
Self-care of minor health problems is facilitated by the availability of a wide range of
nonprescription, or over-the-counter (OTC), drugs. The United States regulatory framework ensures
that OTC drugs are safe and effective when used as directed. OTC drug labels serve as the primary
means of communicating drug-specific information to consumers. By definition, OTC drugs are
available to consumers without a requirement for consulting with a healthcare professional. As a
result, an OTC drug’s label must on its own be able to effectively communicate to an average consumer
the information required for safe and appropriate usage. In the United States the required Drug Facts
Label (DFL) was designed to enhance readability and accessibility of information while ensuring a
more consistent label format across OTC products [1]. Initial tests by the United States Food and Drug
Administration (FDA) found that the DFL consistently outperformed previously used labeling in terms
of consumer preference and readability [1]. Follow-up studies also found that the DFL facilitated faster
acquisition of information compared to prior labeling [2]. However, comprehensive testing to optimize
the DFL format was not done, nor was full testing done to assess whether the format was optimal for
all potential OTC products.
The utility of the DFL is evidenced by the wide use of OTC drugs by consumers to meet a variety
of health needs with an overall outstanding safety record. However, the DFL by nature is a static,
non-customizable, text-based communication tool and research has suggested that expanding the scope
of indications and drugs available to consumers OTC may require changes to the DFL. The purpose of
this review is to provide an overview of research on OTC labeling during the nearly 20 years since
the introduction of the DFL. In doing so, the DFL’s effectiveness as a communication tool is assessed
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and opportunities for improvement in consumer-directed OTC communications are highlighted,
emphasizing potential avenues to leverage pharmacists’ expertise and adjunctive technologies.
2. The Drug Facts Label as a Communication Tool
While an important step forward in providing a more systematized and consumer-focused
method for communicating OTC drug information, the question remains as to whether the DFL is an
optimized communication tool. In its pivotal role, the DFL faces a myriad of challenges and must serve
numerous communication objectives. The DFL must effectively communicate a number of specific
messages required for the safe and effective use of the drug. Conceptually, these messages may be
divided into those required for self-selection, appropriate use of the drug, and deselection if required
(Table 1). Self-selection refers to the assessment of whether the drug is “right for me” based on the
consumer’s specific health status. Appropriate use includes information on dose and duration of use.
Deselection, or discontinuation of use, may be necessary if adverse events develop or the consumer’s
health status changes. Each message must be structured in language and format so that the average
consumer can understand the material. For some products, a dozen or more distinct messages may be
required, posing significant challenges for manufacturers to create effective labels and for consumers
to access and heed the information.
Table 1. Examples of key messages in the Drug Facts Label taken from actual OTC products.
Message Purpose How Is Message Used? Examples Messages on DFL
Self-selection
Information required to determine if the
drug is right for their condition based on
their personal health status
Uses: “Temporarily relieves minor aches and pains”
Do not use: “If you ever had an allergic reaction to any other pain reliever”
Ask a doctor before use if: “The stomach bleeding warning applies to you”
Ask a doctor or pharmacist before use if you are: “Taking any other drug”
Warnings: “This product contains an NSAID which may cause severe stomach
bleeding. The chances are higher if you are age 60 or older”
If pregnant or breast feeding, “ask a health professional before use”
De-selection
Alerts consumer of need to discontinue use
if inadequate response, a potential adverse
event develops, or if there is a meaningful
change in their health status
Stop use and ask a doctor if: “Pain gets worse or lasts more than 10 days”
Information in Do not use, Ask a doctor before use if, Ask a doctor or
pharmacist before use if you are, Warning, and If pregnant or breast
feeding sections may apply if health status changes
Directions for safe use
Instructs consumer on how to use the
product to maximize benefit and
minimize risk
When using this product: “Take with food or milk if stomach upset occurs”
Directions: “Take 1 tablet every 4 to 6 h while symptoms persist”
A well-designed DFL will be ineffective if not read by consumers. Unfortunately, multiple
studies suggest that less than half of consumers read the entire package labeling before taking OTC
medicine [3,4]. For example, only 48% of subjects stated that they always read the usage instructions
for OTC pain relievers before use [3]. Similarly, another study found that only 42% of subjects said they
read everything on the label when taking an OTC medication for the first time and only 26% report
reading the active ingredients at first use [4]. Eye-tracking studies also suggest consumers spend less
time viewing warnings compared to other aspects of package labeling (e.g., the brand name) [5,6].
Indeed, brand names may bias some consumers against comprehensive review of the DFL [7].
Further, even when consumers read and understand the information on the DFL, the question
remains as to whether they behave consistently with the information provided. Unintentional harm
from improper use of OTC products is an important public health concern. Research shows that
many consumers exceed daily dosage recommendations for products such as acetaminophen [8,9] and
nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen [4,10].
These observations make clear the complexity of DFL construction and its importance for safe
and effective use of OTC drugs. The challenges faced by consumers in using the DFL also make clear
the importance of the pharmacist and emerging technologies as potential resources for consumers
making OTC product decisions, and necessitate that pharmacists understand the limitations of the
OTC DFL.
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3. Label Comprehension, Self-Selection, and Actual Use Studies
Studies of the DFL’s ability to achieve central communication objectives for specific drugs are
often conducted as part of an application to switch a drug from prescription to OTC status. Such
studies are used by regulators to determine whether consumers will be able to safely and effectively
utilize a drug in an OTC environment (i.e., using information on the proposed labeling instead of
a healthcare professional) [11]. Some consumer research studies of the DFLs for specific drugs are
published in peer-reviewed journal articles [12–17], while others can be found in the meeting materials
posted by the FDA’s Nonprescription Drug Advisory Committee [18].
OTC label studies include label comprehension studies, self-selection studies, and actual use
studies [19]. Label comprehension studies evaluate consumers’ ability to read and comprehend
the DFL. In a typical label comprehension study, consumers are provided the proposed DFL and
their understanding of label information and/or behavioral intentions are measured [20,21]. A label
comprehension study is not a memory test, and subjects have access to the DFL while answering the
questions. A typical self-selection study investigates consumers’ ability to apply DFL to their own
personal medical situation and determine whether the drug is appropriate for them to use [22]. Actual
use studies assess consumer decision-making and behaviors when using the drug in as naturalistic a
setting as possible. An actual use study evaluates the DFL by attempting to simulate actual purchase
environments in which participants make self-selection decisions (i.e., deciding whether to purchase
and use a particular drug), whether they deselect for continued use based on their response to the
drug, and if they follow the directions for use [19]. Diaries or follow-up surveys are often conducted
with purchasers of the drug to evaluate their actual use of the product (e.g., dosage and frequency,
etc.) [14,15,17,23]. In some situations, a self-selection study may be conducted as a component of an
actual use study [22].
Importantly, the results of label comprehension studies, self-selection studies, and actual use
studies may need to be viewed as idealized estimates of DFL comprehension and appropriate usage in
the post-approval marketplace. Label comprehension and self-selection studies allow full access to
the DFL while answering questions and thus inherently include some degree of cuing to specific label
information. Similarly, despite efforts to maintain realism in the design of self-selection and actual use
studies, the mere fact that an individual knows they are participating in a study (e.g., completing a
questionnaire or filling out a diary each day while using a medication) may bias behaviors towards
DFL compliance. These issues are explored further in the sections that follow.
3.1. Label Comprehension
Results of label comprehension studies often suggest high levels of comprehension when
testing understanding of individual statements or warnings on the label. For example, in a label
comprehension study for omeprazole, results suggested that 95% of subjects understood that the dose
was 1 tablet, 91% understood the product should be taken for 14 consecutive days, and to contact
a health care professional before using beyond 14 days [24]. For lovastatin, a label comprehension
study showed comprehension rates above 90% on questions measuring understanding of specific
drug information such as the condition treated by the drug, frequency of use, and dosage [25].
Label comprehension studies for lovastatin also showed similarly high rates (~90%) of comprehension
for warnings related to individual safety factors such as age, pregnancy, breast feeding, liver disease,
and the need to discontinue use if one develops muscle pain [26].
3.2. Self-Selection and Actual Use
Results assessing intended or actual behaviors such as self-selection in a self-selection study or
product use in an actual use study may exhibit lower rates of compliance/heeding of the label than
suggested by label comprehension results. In contrast to label comprehension study measures of
individual label statements, proper self-selection and use can be more complex, requiring integration
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of multiple pieces of information (e.g., simultaneously meeting multiple criteria for appropriate use
or adhering to the correct dosage amount, interval, and duration of use). For example, an actual use
study of omeprazole found that 19% of subjects did not meet all six criteria specified on the label
for appropriate self-selection, 21% did not comply with the recommended drug regimen, and 5%
exceeded the recommended number of doses [27]. FDA reviewers of an actual use study for lovastatin
determined that only 1% (n = 3 out of 209) of subjects who believed they could immediately start
taking the drug were correct on all of the label criteria specified for appropriate self-selection, including
age, low density lipoprotein cholesterol concentration, risk factors, medical history, pregnancy status,
and other medication usage [26]. Of course, expecting consumers to answer correctly across multiple
different items presents a significant challenge for any means of communication. Nevertheless, these
examples highlight the difficulty in communicating complex information using the DFL alone and the
room for improvement that could be facilitated by alternative labeling strategies or by supplemental
assistance from pharmacists or adjunctive technologies.
It is also critical to interpret wrong answers in label comprehension studies, incorrect self-selection
in self-selection studies, and/or inappropriate usage behavior in actual use studies in the context
of the clinical importance of the message being assessed [28]. In most cases, small deviations from
the desired behavior do not affect either efficacy or safety of the drug, and can thus be accepted.
However, for messages where noncompliance poses a serious risk to the consumer a high magnitude
of correct comprehension/behavior should reasonably be required.
Overall, these results suggest that often a DFL can be developed which performs reasonably
well in label comprehension study settings where individual pieces of label information are assessed.
However, the results of these self-selection studies and actual use studies suggest that the DFL struggles
to communicate more complex or multifaceted concepts required to make decisions about self-selection
and use. Furthermore, despite the large numbers of label comprehension, self-selection, and actual
use studies conducted and their role in regulatory decision-making, their ability to predict real-world
behaviors is uncertain. Studies of drugs already approved for OTC use suggest instances of consumer
misconceptions of label elements or noncompliance. For example, a recent study found that only
about 24% of users of acetaminophen-containing products knew both that acetaminophen was an
active ingredient and that they should avoid concomitant use of more than one product containing
acetaminophen [29]. Follow-up diaries showed that subjects who lacked knowledge about active
ingredient contents and/or concomitant use were more likely to have deviated from the label directions
when taking drugs containing acetaminophen [29]. In another example, Shi et al. (2004) found that
54% of purchasers of histamine2-receptor antagonists made self-selection errors (i.e., chose the product
when they did not meet the criteria listed on the label). Further, a study of female purchasers of OTC
phenazopyridine found significant gaps in knowledge about the drug, including the indications for use
of the drug and its function (e.g., 43% incorrectly believed phenazopyridine functions as an antibiotic
as opposed to its actual function as a urinary tract analgesic) [30].
The overall limitations of the DFL as assessed through label comprehension, self-selection, and
actual use studies has led to more focused research to identify individual-level factors associated
with a failure to comprehend and heed DFL instructions. An understanding of these factors is also
an important step in improving DFL effectiveness and leveraging the role of the pharmacist and
technology tools.
4. Individual-Level Factors and the DFL
4.1. Health Literacy, Visual Ability, and Language Barriers
Health literacy has been defined as “the degree to which individuals have the capacity to obtain,
process, and understand basic health information and services needed to make appropriate health
decisions” [31]. Though some have raised concerns about construct validity and the existence of
several different measurement tools [32–34], health literacy is a major consideration in DFL studies.
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Indeed, many label comprehension, self-selection, and actual use studies report outcomes separately
by literacy level in an effort to address concerns that some groups may not be as well-equipped to
process DFL information. For example, studies have found that limited health literacy is associated
with less knowledge about OTC active ingredients and is an impediment to label comprehension [3].
Additionally, a study found that individuals with limited health literacy were less likely to consider
active ingredient information when making decisions about pediatric cough and cold medication [35].
Similarly, consumers with limited health literacy were more likely to exceed recommended dosages
by taking two or more acetaminophen-containing products simultaneously in a simulated usage
scenario [36].
Limited health literacy and visual impairment were both found to be independently associated
with improper OTC dosing [37]. Having English as a second language is also associated with lower
health literacy (including when measurement instruments are translated into an individual’s native
language) [38,39], although language barriers can independently impede label communication [40].
In addition, a quantitative analysis of label language complexity found that the reading ease and grade
level scores for a sample of 40 OTC products were beyond the capabilities of an average consumer [41].
Adding a further challenge, FDA guidelines specify use of 6 point font for the body text of the DFL [42]
which may impede communication with visually impaired individuals or older adults [43].
To summarize, the DFL is a static, text-based medium written in English, which means that it
is inherently limited in its ability to serve the needs of limited literacy, visually impaired, and/or
non-English speaking populations. These populations are thus vulnerable to poor comprehension and
heeding of the DFL.
4.2. Older Adults
Older adults have been identified as an important group for study with respect to OTC use as
they represent a growing segment of the population and are heavy users of OTC (and prescription)
products [38,44]. One study found that younger consumers processed label information faster than
older consumers, although label comprehension did not differ across groups and was relatively high
overall [45]. Importantly, as a group, older adults (age 65 and up) exhibit lower levels of health literacy
than younger age groups [44] which, as discussed above, inhibits understanding of and compliance
with DFL instructions [46]. Potentially offsetting these factors, older consumers were found to be more
engaged when making OTC purchases and more likely to read the label completely than younger
consumers [47]. Studies have found no age-related differences in the likelihood of exceeding the dosage
of acetaminophen [8] or NSAIDs [10], perhaps implying that increased engagement or label reading
by older consumers may compensate for other disadvantages. Nevertheless, while age may heighten
the level of personal relevance or involvement with OTC drug purchases, there are issues inherent to
aging (e.g., decreased cognitive function, reduced vision) that may hinder effective interaction with
OTC drug labeling. For instance, older adults preferred and performed better in label comprehension
tests when the labels used larger print sizes (e.g., 10 and 7 point font vs. 4 point font) [43].
4.3. Knowledge, Attitudes, and Beliefs
Preexisting attitudes and beliefs about OTC drugs can limit attention to and/or result in overriding
of DFL instructions. For instance, individuals perceive OTC drugs as less risky than prescription
drugs [48] and consumers may hold the erroneous belief that OTC drugs are essentially risk-free
even if taken incorrectly [49]. Likewise, some individuals believe that they can choose their own dose
regardless of DFL instructions and this belief is associated with exceeding dosage limits for common
OTC products [8,10]. Further, 68% of participants in a study of OTC histamine2-receptor antagonists
stated that the package labeling had little to no influence on their decision-making [50]. In another
study, 51% of participants stated they would be unlikely to read allergy-related information on an
OTC label and 80% stated that they would be unlikely to keep the medication packaging (carton) for
reference when they begin using the drug [51]. Therefore, even if consumers attend to and understand
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the information provided in the DFL, their existing beliefs and attitudes may lead them to behave
discordantly or to ignore the package labeling altogether. Such misconceptions and apathy toward
OTC instructions suggests a broader need to educate consumers about OTC products in a way that
goes beyond what the DFL can be expected to accomplish on its own. As credible experts located at
the point-of-purchase, pharmacists are well-suited to deliver this type of information.
5. Tests of Modifications to the Drug Facts Labeling
In the context of the limitations identified above, a variety of studies have investigated
modifications to the DFL, such as additional or revised warnings and graphical icons, to improve
communication of specific drug information.
5.1. Warnings
As noted above, consumers’ preexisting beliefs about the safety of OTC medications may result in
their discounting of label warnings [49] and thus efforts have been made to increase the effectiveness
of these warnings. Acetaminophen is a safe OTC analgesic when used as directed, but can cause
liver injury when label doses are exceeded. A label comprehension study of revised liver damage
warning for acetaminophen found that labels more clearly stating organ damage along with more
prominent information about the seriousness of overdose and how to take action led to more accurate
behavioral intentions than with existing OTC labeling [52]. Moreover, a within-subjects study found
that perceived risk of liver damage for acetaminophen was higher when labels contained revised
warnings from the FDA (“organ-specific warning label”) [53]. Studies also suggest that details matter
when it comes to warning design and highlight the importance of consumer testing. A test of
several alcohol warnings on acetaminophen labeling found that recall was highest for an explicit
warning featuring red print and detailing the hazards of combining acetaminophen with alcohol [54].
In addition, consumers in a study of OTC ibuprofen labeling preferred more explicit warnings using
bulleted, plain language to communicate drug allergy information [55]. These results from simulated
settings highlight the potential utility of warnings, but also emphasize the importance of validation
using rigorous consumer-testing. Unfortunately, the addition of warnings to the DFL is frequently
recommended without such testing [56–58]. As a result, there is little data to validate the effectiveness
of such warnings nor the consideration that continued addition of warnings adds to the overall length
and complexity of the DFL for some products. Highlighting one warning may focus a consumer’s
attention to that specific warning but result in less attention to other portions of the label. This
represents yet another area where pharmacists and technology can complement the DFL to help
consumers determine which warnings are most relevant and heed them accordingly.
5.2. Icons
Icons provide an alternative to text for communicating information. Icons have been studied
in an effort to enhance awareness of acetaminophen as the active ingredient as a means to reduce
the risk of overdose (e.g., by concomitant use of two medications containing acetaminophen). In a
qualitative focus group and interview study, consumers supported the idea of including icons on OTC
packaging to help facilitate identification of acetaminophen as the active ingredient and they also
responded favorably when shown prototype icons for this purpose [3]. In a comparative study of
prototype acetaminophen icons, participants preferred icons that could be more directly connected
to the active ingredient, such as using icons with the letters “Ac”, “Ace”, and “Acm” instead of
“APAP” (an often used abbreviation for the name of the chemical compound) [59]. A study involving
hypothetical scenarios found that an acetaminophen icon (vs. no icon) reduced dosing errors due to
concomitant use of two medications containing acetaminophen [60]. Of note, this study also suggested
that the effect of the icon was larger among individuals with limited literacy (less than 9th grade level)
suggesting the potential utility of using graphical or visual cues to more effectively communicate
with this segment of consumers. An experimental study of parents found that pictographic icons
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that graphically illustrated proper dosing may help limited literacy individuals avoid dosing errors
for liquid preparations of pediatric acetaminophen [61]. However, it is important that consumers
understand what a particular icon means through prior orientation and education efforts [49].
In general, evidence supports the potential for enhanced warnings and icons to aid in
communication effectiveness of specific drug information. However, the design details are important
and icons must be carefully designed and tested to ensure the best chance of success [49,54]. Again, it is
important to note that the studies to date have taken place in experimental or hypothetical settings and
it is still unknown whether their effects will translate to the general marketplace. Another consideration
that has yet to be explored systematically is how modifications to certain aspects of the labeling (e.g.,
icons or warnings) impact attention to or comprehension of other aspects of the labeling. A strategy
of continuously adding more content to the label (icons, warnings, etc.) increases the likelihood of
information overload [62] and makes it more difficult for any individual consumer to extract the
information most relevant to them. This reinforces the appeal of dynamic, customizable resources
such as pharmacist and technology-based communication which can be tailored to the individual
circumstances of each consumer.
6. Discussion and Future Opportunities
Despite the discussed limitations in the communication effectiveness of the DFL, current OTC
drugs maintain a remarkable safety profile overall and are used by the vast majority of consumers
without issue. Yet, it is clear from prior research that the DFL falls short in some areas, most notably in
the ability to tailor the communication to an individual user’s specific situation (i.e., other medications,
literacy level, language ability, age, pre-existing beliefs/attitudes, etc.) or when more complex decision
algorithms are required (e.g., statins). In addition to the improvements in the DFL itself suggested
above, expanding the role of pharmacists and leveraging technology offer opportunities to further
improve consumer communication and decision-making on the use of OTC drugs (see Table 2).
Table 2. Challenges to Drug Facts Label (DFL) effectiveness and possible mitigation strategies.
Challenge to DFL Effectiveness Description(s) Possible Mitigation Strategies
Challenge 1:
Static and non-customizable
Cannot uniformly meet the needs
of specific consumer populations,
for example:
• Limited literacy
• Visually impaired
• Language barriers
• Older consumers
• Pre-existing beliefs/attitudes
that override DFL messaging
Alternative DFL Strategies
• Icons or enhanced warnings calling attention to critical
drug-specific information
# Must also ensure consumers can understand the meaning
of icons (e.g., including text descriptions or through prior
orientation/education efforts)
• Larger text to enhance accessibility of key
drug-specific information
Pharmacist
• Credible, trusted resource at the point-of-purchase
• Engage with consumers to understand individual
needs/limitations
• Provide information and guidance most relevant to each consumer
• Educate consumers about safety/risks associated with OTC drugs
Technology
• Dynamic, customizable approaches with flexible implementation
# Implementable via mobile application, kiosk/display at
point-of-purchase, online, etc.
• Query individual characteristics and deliver
personalized information
• Can use multimedia to create more engaging and/or
persuasive content
• Accessible delivery of information (e.g., text, sound, and/or video)
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Table 2. Cont.
Challenge to DFL Effectiveness Description(s) Possible Mitigation Strategies
Challenge 2:
Communicating complex,
multi-attribute criteria for
decision-making
Consumers have difficulty
understanding more complex DFL
information
Consumers struggle to integrate
multiple DFL criteria necessary for
appropriate self-selection and
usage decisions
Alternative DFL Strategies
• Icons or enhanced warnings to that clearly highlight most
important self-selection criteria
• May be combined with additional education efforts to assist
consumers with interpreting DFL information
Pharmacist
• Guide consumers through each aspect of self-selection criteria
• Dialogue to confirm understanding of usage instructions
• Opportunity to answer questions and/or provide supplemental
information about directions for safe use and de-selection
Technology
• Ability to create interactive, step-by-step decision aids
• Post-purchase follow-up# Real-time collection of usage information
# Reminders, reporting of adverse events, etc.
6.1. Expanded Role of Pharmacists
Pharmacists remain a trusted resource [63] located at the point-of-purchase for many OTC drugs.
Increasing dialogue between pharmacists and consumers of OTC drugs would bridge some of the
previously identified gaps in OTC label communication. Pharmacist-consumer interaction at the
point of purchase can allow for pharmacists to ask questions and communicate key information
tailored to an individual’s specific situation. For example, pharmacists can provide a more detailed
discussion of risks or side effects [64] which may be frequently underestimated by consumers of
OTC products [49]. Pharmacists can also help consumers navigate more complex drug information,
including decisions involving integration of multiple criteria (e.g., self-selection of a statin). The utility
of pharmacist-consumer interaction is even more important as drugs with more complex self-selection
algorithms or a potential for serious adverse side effects are considered for prescription-to-OTC
switch [65,66]. Further supporting this opportunity, pharmacist advice and guidance for OTC drugs
has previously been found to help consumers make more appropriate medication decisions [67].
Consumer-pharmacist interactions can only mitigate the limitations of the DFL if the consumers
who need help recognize the need and the availability of pharmacist assistance. This represents
another important opportunity for consumer education. Conversely, pharmacist workloads are
high in the United States [68] and consumers may be frustrated by delays in being able to talk to
a pharmacist. In addition, there are additional barriers related to economic incentives (e.g., lack of
payment and/or time spent away from other revenue-generating activities) for OTC drug consultations
and some pharmacists may need additional training on how to best navigate OTC-related consumer
interactions [69]. Thus, steps should be taken to facilitate these communications in the contemporary
pharmacy environment [70]. These steps could range from consumer education campaigns, redesigning
the physical layout of pharmacies to promote communication [71], and/or supplemental training
for pharmacists. Regulatory agencies and other organizations can also work to incentivize increased
consumer-pharmacist interaction related to OTC drugs. In selected cases, interaction between
pharmacists and consumers could be encouraged by requiring that a specific OTC drug only be
sold at locations and time when a pharmacist is available or in extreme cases that certain drugs be
located “behind-the-counter” of the pharmacy. At the same time, it will also be important to design and
implement these efforts with an eye toward continuous evaluation and identification of best practices.
6.2. Adjunctive Technologies
Despite advances in the use of visual display panels to interact with individuals and the rise in
the use of smartphones and other connected devices, OTC labeling and communication efforts have
yet to leverage such technological advances. Many consumers are already using tablet devices to
provide medical histories when they visit physicians or mobile applications to monitor aspects of
a healthy lifestyle. These same technologies can be used as adjuncts to the DFL to aid in consumer
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communication and decision-making. The FDA has recently acknowledged the potential to harness
these capabilities in their July 2018 draft guidance on Innovative Approaches for Nonprescription Drug
Products [72]. This draft guidance suggests FDA willingness, for regulatory purposes, to consider
adjunctive technologies, such as mobile applications, multimedia displays, websites, etc. as part of
the labeling or as conditions of safe use, in addition to the DFL. While a comprehensive review
of adjunctive technologies is beyond the scope of this review, broad applications can be easily
conceptualized. For instance, interactive decision aids could be implemented at the point-of-purchase
that could allow consumers to input personal characteristics or symptoms and receive guidance for
self-selection or other pertinent drug information (e.g., taking into account other medications or allergy
information) [73]. Technology facilitates multimedia (text, audio, and/or video) delivery of OTC drug
information which may be more engaging and persuasive for some users and more accessible to those
with limitations related to literacy, vision, or language. Mobile and/or online applications can be
developed to communicate with consumers post-purchase in ways that are impossible with current
labeling. Post-purchase communications could include reminders or ongoing instructions that are
customized to the individual user. Technologies could also be used to measure usage patterns or even
adverse events. Of course, rigorously designed studies will be needed to test, validate, and optimize
these systems.
7. Conclusions
Expanding access to safe and effective drugs without a prescription aligns with the desire of
consumers to be more engaged in their own health care and society’s need for efficient health care
delivery [74]. Despite its success to date, the inherent limitations in the DFL discussed above represent
a potential barrier to optimizing and increasing OTC options for consumers. Recognizing these
limitations is an important step in improving OTC drug communication. Leveraging pharmacist
expertise and technological capabilities to provide a more dynamic, user-oriented experience have the
potential to move beyond what can be done with an optimized, customized DFL. Doing so has the
potential to improve consumer outcomes through better comprehension and compliance for existing
drugs and could also expand consumer access to additional drugs where the current DFL label alone
would be insufficient for OTC approval.
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